Tuberculosis is a global health problem with the existence and spreading of multidrug resistant and extensive drug resistant strains. The development of new drugs for tuberculosis that inhibit different activities than the current drugs is thus urgent. The prokaryotic ubiquitin like protein proteasome system is an attractive target for the development of new drugs. Using a Pup-based fluorogenic substrate, we screened for inhibitors of Dop, a depupylase, and identified I-OMe-Tyrphostin AG538 (1) and Tyrphostin AG53 (2). The hits were validated and determined to be fast reversible non-ATP competitive inhibitors. The SAR was established by testing 27 synthesized analogs of 1 and 2. Several of the synthesized compounds also inhibited the depupylation of a native substrate, FabD~Pup. Importantly, the pupylation and depupylation activities of PafA, the sole Pup ligase in M. tuberculosis, was also inhibited by some of these compounds. With the identification of the first described lead compounds for Dop and PafA inhibition, this study shows that high throughput screening can be a successful strategy for this purpose.
. Fluorogenic assay to probe Dop activity, based on truncated Pup(33-63)-Glu and AMC.
In our efforts to find inhibitors to specifically target accessory factors of the Mtb PPS in the search for new drugs against TB, and to develop tools to study the mechanisms of action of these enzymes, we have previously developed a fluorogenic assay reagent to probe the activity of Dop in vitro that allows high throughput screening to identify inhibitors (Figure 2 ). 27 The reagent is based on synthetically made, truncated Pup (Pup33-63) with a terminal Glu attached to 7-amino-4-methyl coumarin (AMC) via its -carboxylate. Cleavage of the AMC-group by Dop , but not PafA, releases AMC, which then fluoresces. Here we describe the use of this reagent in a small-molecule screen to identify inhibitors for Dop. Interestingly, several Dopinhibitory compounds also inhibited both PafA activities. The hits were characterized in both biochemical and cell-based assays together with a structure activity relationship (SAR) study.
Results and Discussion
Screen set up for Dop inhibitors. We screened a library of 1280-pharmaceutically active compounds (Lopac) for Dop inhibitors using our previously developed fluorogenic Dop substrate, Pup(33-63)-Glu(AMC). 27 We identified several hits in this screen, including I-OMe-Tyrphostin AG 538 (1) and Tyrphostin AG538 (2) , which were the most potent compounds ( Figure 2 ). Both molecules consist of a cis-benzylidenemalonitrile backbone that is on both sides connected to aromatic ringsCompounds 1 and 2 have been identified before as inhibitors for several kinases with various modes of inhibition. For example, 1 and 2 act as substrate compettive inhibitors of the IGF-1 Receptor Kinase 28 , while they inhibit phosphoinotiside kinase PI5P4K by competing with ATP. 29 On the other hand, oxidative stress-sensitive Ca 2+preamble channel TRPA1 and TPRM2 activated by H2O2, are inhibited by scavenging hydroxyl radicals. 30, 31 To validate the hits, we repeated the inhibition experiment with 1 and 2 determined the IC50 values ( Figure 3 ). Values of 0.52±0.12 and 0.3±0.03 M were found for 1 and 2 respectively. We next assessed the specificity of 1, by performing a 'ratio test' (Supplementary information Figure 1 ). 32 In this assay, the IC50 value of 1 was measured at a routine and 10-fold increased To get an understanding of the mode of Dop inhibition by 1, we first tested if different incubation times of 1 together with Dop would result in a change of IC50 value. If 1 were irreversibly and covalently inhibiting Dop, lower IC50 values would be expected with longer incubation times, because 1 has more time to form a covalent bond with Dop. Thus, the IC50 values were determined with 5 and 60 minutes pre-incubation of Dop with 1 before addition of the substrate (Supplementary Figure 2) . The IC50 values did not change significantly (0.47±0.05 M for 5 min incubation vs. 0.71±0.08 M for 60 min incubation) indicating a noncovalent mode of inhibition. This was further confirmed by the results of a 'jump-dilution' assay (Supplementary information Figure S3 ). 33, 34 In this assay Dop was pre-incubated for 30 minutes with a concentration of 10 times the IC50 value for 1, followed by a 100-fold dilution and reassessment of the activity. For 1, complete restoration of Dop activity was observed after dilution, suggesting that there was a fast re-equilibration of the Dop-1 complex and that 1 is a fast-reversible inhibitor.
Next, we tested if 1 inhibited Dop by competing with the binding of ATP. Therefore, we first determined the Km of ATP for Dop (0.32±0.03 mM, Figure 4A ). Subsequently, the IC50 value was determined in the presence of eight different concentrations around the Km of ATP ranging from 0.1-6.4 mM ( Figure 4B ). In the case of an ATP competitive inhibitor, a positive relationship between the IC50 and log[ATP] was expected. 34, 29 Because the IC50 did not significantly increase with higher ATP concentration, we concluded that 1 is not an ATP competitive inhibitor. With 1 validated as a specific, fast reversible and non-ATP competitive inhibitor for Dop, we used it as lead compound in the subsequent SAR study focusing on variation of substituents on the aromatic rings followed by modification of the benzilydenemalonitrile core ( Figure 5 ).
In this work, a total number of 27 compounds were evaluated for their potency to inhibit the activity of Dop using the Pup(33-63)-Glu(AMC) assay by measuring the IC50 values (Table 1 ). Chemistry. The target compounds were close derivatives of 1 and 2 (Table 1) . The benzylidenemalonitrile core (5, Scheme 1) was conveniently prepared through a Knoevenagel condensation reported by Kaufmann 35 involving treatment of benzaldehydes (3) and malonitrile (4) with piperidine in ethanol to give the desired compounds in 35-85% yield (Scheme 1).
For the synthesis of compounds 10a-10m, bearing two hydroxyl groups on the malonitrile part, we envisioned 3,4-dimethoxymethyl malonitrile 8 as the reaction partner for the Knoevenagel reaction. Compound 8 was synthesized from 3,4-dihydroxybenzoic acid methyl ester that was efficiently MOM-protected using K2CO3 in acetone to afford 6 in quantitative yield. Subsequent substitution of the ester 7 using deprotonated acetonitrile afforded malonitrile 8 in 95% yield. The Knoevenagel reaction using 8 proceeds smoothly with a range of benzaldehydes. Deprotection of the hydroxyl groups is conveniently achieved using a mild method that employs KHSO4 coated silicagel 36 to afford the final compounds 10a-10m in good yield after purification.
Compound 12 that is lacking the nitrile moiety on the Michael acceptor was synthesized from aldehyde 3a and acetophenone (11) using KOH as base in a similar Knoevenagel condensation (Scheme 2A). Complete reduction of the Michael acceptor to alcohol 13 was achieved in 22% yield as a 2:1 mixture of diastereomers by treating 5a with NaBH4 in methanol for 15 minutes (Scheme 2B). Additionally, we selectively reduced the carbonyl of 5a by applying Luche's reduction conditions (NaBH4/CeCl3) to obtain 14 in 50% yield (Scheme 2C).
Unfortunately, our attempts to selectively reduce the double bond while maintaining the carbonyl moiety were unsuccessful. Scheme 1. Synthetic routes for the synthesis of compounds 5 and 10 a a Reagents and conditions: (a) piperidine, EtOH, room temperature 16h (35-85%); (b) MOMCl, K2CO3, acetone 60 °C overnight (95%); (c) LiCH2CN, THF, -78 °C, 2h (95%); (d) ArCHO, piperidine, EtOH, 20 °C overnight; (e) KHSO4·SiO2, CH2Cl2, r.t. overnight (20-77% over two steps). a Reagents and conditions: (a) NaOH, EtOH, room temperature, 16h, (44-69%); (b) NaBH4, MeOH, 0 °C, 60 min (22%, 2:1 mixture of diastereomers); (c) NaBH4, CeCl3, MeOH, 0 °C, 1h (50%).
SAR study. Our first aim was to see whether the catechol ring coulb be removed in order to exclude a redox mechanism for inhibition. The first series of compounds thus focused on variation of R 1 where R 2 was fixed as a phenyl (entries 1-14, Table 1 ). Compound 5a lacking the catechol group as the R 2 phenyl ring compared to 1 and 2, showed a 10-fold decrease in potency (5.4 M, entry 1) indicating that the OH-groups are not crucial for inhibition but are important for the potency. On the other hand, the parent compound (5b) was inactive indicating that thus the R 1 -substituents are essential for inhibition (entry 2). Restoration of the p-hydroxyl (5c) and the m-methoxy (5d) group did not result in active compounds (entries 3 and 4), while on the other hand, 3,4-dihydroxyphenyl as R 1 (5e) was moderately active (32 M, entry 5).
Exchange of one hydroxy moiety to a nitro group (5f, 23 M, entry 6) or a methoxy group on position 3 had no significant effect on the IC50 values (5f, 23 M, entry 6; 5g, 26 M, entry 7). N,N-dimethylphenyl (5h) as R 1 was inactive (entry 8).
The effect of the substitution pattern of the R 1 -phenyl ring was further investigated. We kept the 3-methoxy-4-hydroxy pattern constant and varied the 5-position of R 1 (entries 9-12).
Adding a methoxy-group on the 5-position (5i) did not result in inhibition of Dop (entry 9), while a chloride (5j) resulted in an active compound with poor activity (72 M, entry 10).
Changing the 3-methoxy group to an ethoxy group and have an additional 3-methoxy on the R 2 phenyl ring (5k) was beneficial since the potency increased a 2-fold to 28 M (entry 11) compared to 5j. Changing the chloride to a bromide with R 2 being a phenyl again (5l) increased the potency further to an IC50 of 20 M (entry 12) compared to 5j.
From the results so far, we concluded that the hydroxy group on the 4-position of R 1 is essential for inhibition, while the potency is dependent on the electronic properties of the groups around the 4-position. To test this hypothesis, we tested compound 5m that is lacking the 4-hydroxygroup compared to 5l and 5n in which the R 1 substituents are shifted one place compared to 5a. Both compounds were inactive (entries 13 and 14), supporting our hypothesis.
We continued to investigate the role of the 3,4,5-trisubstitution on R 1 with R 2 being 3,4dihydroxyphenyl, like in the original two hits (entries [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . This change of R 2 should deliver more potent compounds compared to the previous series. To further investigate the role of the substitution pattern on R 1 , we started with compound 10a, which lacks the iodine moiety compared to 1. The presence of a group on the 5-position seemed to be crucial based on the observation that 10a was inactive (entry 13). The presence of an electron withdrawing nitrogroup (10b) restored potency (4.1 M, entry 15). Subsequent removal of the methoxy group on the 3-position (10c) led to a significant loss of potency (96 M, entry 15), while additional removal of the 4-hydroxygroup (10d) again rendered an inactive compound (entry 18). This indicates that both the 3-methoxy and 4-hydroxy are essential for potent inhibitors. We thus continued investigating the effect of different substituents on the 5-position (entries [19] [20] [21] [22] [23] [24] .
Interestingly, when an electron donating methoxy group was placed on the 5-position (10e), this compound appeared to be inactive (entry 19) . Electron withdrawing groups appear to be required on the 5-position. When we substituted the 5-position with a phenyl (10f) the compound was moderately active (41 M, entry 20) . It was however, not beneficial for the potency to add a more electron poor 4-fluorophenyl on position 5 (10g, entry 21). To further investigate the electronic properties, we tested analogs containing a Cl, Br or F on the 5position (10h-10j, entries [22] [23] [24] . 10h and 10i were slightly less potent than the original hit 1 The hybrid compound (10k) based on both 1 and 2 that has the 3-methoxy moiety replaced for a hydroxy moiety, was the most potent compound from the synthesized analogs (0.29 M, entry 25). In conclusion, the 4-hydroxyl group on the R 1 -phenyl ring is essential for inhibition and the potency is most likely dependent on its acidity that is regulated by the 5-substituent.
The two hydroxyl groups on the R 2 -phynyl ring increase the potency, but are not essential. a the reported values are the means of one experiment ± SD run in triplicate. b compound was obtained from a commercial supplier.
Having established initial SAR, we turned our attention to modification of the core part.
Compound 1 contains a Michael acceptor in the form of an ,-unsaturated ketone functionalized with a cyano group on the 3-position. The cyano group was previously designed as a modulator for the reactivity of the Michael acceptor which as a result, reacts reversibly covalent with cysteine nucleophiles whereas ,-unsaturated ketones react irreversibly with cysteine residues. 37 Because the inhibition of Dop by 1 was determined as fast reversible (vide supra), it is therefore unlikely that 1 binds reversible covalent with a nucleophilic residue of Dop. As a result, we do not expect the Michael acceptor to be a crucial structural element for inhibition. We synthesized a series of analogous compounds in which the Michael acceptor was systematically modified to verify this hypothesis ( Table 2) . a The reported values are the means of one experiment ± SD run in triplicate.
Compound 12 that lacks the cyano group compared to 5a (5.4 M; Table 2 , entry 1) was still active, but six-fold less potent (31 M; Table 2 , entry 1). On the other hand, compound 13, in which the carbonyl is selectively reduced to the alcohol, was less potent (57 M; entry 2). Complete reduction of the ,-unsaturated system (14) resulted a complete loss of activity (entry 3). Although the full cis-benzylidenemalonitrile backbone is not essential for inhibition, selective reduction greatly influenced the potency of the compounds. A possible explanation could be that the rigidity of the unsaturated system is keeping the geometry of the molecule optimal for inhibition. Mtb FabD-His6. 38 Note that FabD can be pupylated on any one of four lysines, resulting in two slightly different migration patterns. 39 With the optimal reaction conditions determined, eight compounds were selected ( Figure   6A ) and tested for inhibition at 100 M in the depupylation assay ( Figure 6C ). Interestingly, the degree of inhibition observed in using the fluorogenic substrate was not consistently reflected in the depupylation assays using a native substrate. For example, compound 2 (IC50 0.13 µM) was identified as the most potent inhibitor, however, it failed to inhibit depupylation The compounds show a different inhibition pattern between the two assay substrates which are most likely explained by a difference in affinity of both substrates for Dop. It appears that the size of the 5-position of the left ring is a more important factor than the electron negativity of this substituent in the depupylation of FabD~Pup. This is illustrated by the completely opposite effects of 2 and 10f between the fluorogenic and native substrate (H vs. Ph). Moreover, the lack of inhibition of 5a underlines the importance of the presence hydroxy groups on the right ring.
Testing the compounds on native
Because Dop and PafA have highly similar sequences and structures, 40 we investigated whether or not these compounds were able to influence the ligase and depupylase activities of PafA using our pupylation substrate FabD. We looked at the pupylation of FabD by PafA in the presence of 100 M of each of the inhibitors (Figure 7 ). Compounds 10k and 2 and 10f completely inhibited pupylation, while 1 and 10i partly inhibited the ligase activity of PafA.
The remainder of the compounds showed no inhibition. Given the structural homology, it is not surprising that inhibitors for Dop also inhibit PafA. However, 2 did not inhibit Dop in the depupylation of FabD~Pup, while it fully inhibits PafA's ligase activity. Apparently, despite the structural homology, small differences in inhibitor structure allow inhibitors to be selective for PafA. Recently, we described a depupylase activity for PafA. Interestingly, PafA cannot deamidate PupQ to PupE or release AMC from Pup(33-63)-Glu(AMC) and appears to be more effective at depupylating inositol 1-phosphate synthetase (Ino1~Pup) than FabD~Pup. 21 Mtb has a highly hydrophobic cell envelope that is impermeable to many molecules, which contributes to the difficulty in treating TB infections. 41 Nonetheless, our goals were to determine whether or not Dop could be targeted for inhibitor discovery as well as identify molecules that may give new insight into the mechanism of catalysis by this highly unique protease. Since our screen identified inhibitors of pupylation as well as depupylation and do not compete with ATP, these molecules may instead affect the positioning of the C-terminus of Pup and its substrate within the active site. The fact that inhibitors for both enzymes in the PPS could be found using this screening approach is likely due to the close structural homology between Dop and PafA.
A recent study showed that a well-characterized serine protease inhibitor, (4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), could inhibit the activities of PafA. 26 inhibition. Ultimately our goal will be to screen for inhibitors that will be able to better penetrate the Mtb cell envelope and have minimal to no toxicity in mammalian cells. Idealy, potential lead series inhibit both Dop and PafA synergistically, which could minimize the acquisition of resistance to these compounds.
Conclusions
In an effort to identify inhibitors of Dop TFA. Fractions containing the product were automatically collected based on observed mass and UV-signal after which they were lyophilized to obtain the pure products. The purity of the target compounds was determined by 1 H-NMR analysis, high resolution mass spectroscopy and shown to be >95% pure prior to biological testing.
Compound 5k was commercially obtained from Enamine ltd. and was declared to be >95% pure. Compound 1 was commercially obtained from Sigma Aldrich was declared to be >95% pure. 
3,4-bis(methoxymethoxy)benzaldehyde

3-(3,4-bis(methoxymethoxy)phenyl)-3-oxopropanenitrile (8
General procedure A, Knoevenagel condensation
The appropriate 2-oxoacetonitrile (1 equiv) and aldehyde (1 equiv) were dissolved in absolute EtOH. A catalytic amount of piperidine was added and the mixture was heated to 65 °C for 30 minutes. The mixture was cooled to room temperature and stirred overnight. The precipitated product was then filtered and the filtrate washed with ice-cold EtOH to obtain the crude product.
General procedure B, MOM-deprotection
The MOM-protected compound (1 equiv) was dissolved in CH2Cl2 followed by the addition of a scoop of KHSO4 supported silicagel. 36 The resulting suspension was stirred overnight and the silica was filtered off. The residu was evaporated and the crude purified using preparative LCMS.
General Procedure C, Chalchone formation
To a stirred solution of KOH (45 equiv) in water cooled to 0 °C, was added dropwise a solution of benzophenone (1.5 equiv) and benzaldehyde (1.0 equiv) in MeOH. The mixture was kept at was poured in ice and the pH was adjusted to 3-4 with 1M HCl and extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over MgSO4 and evaporated to obtain the crude product. 
